$5.88
6.91% yesterday
Nasdaq, May 16, 10:11 pm CET
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Jaguar Health, Inc. Stock price

$5.88
+0.27 4.79% 1M
-18.60 75.98% 6M
-19.37 76.71% YTD
-424.17 98.63% 1Y
-43,644.12 99.99% 3Y
-168,710.37 100.00% 5Y
-2,338,910,431.62 100.00% 10Y
Nasdaq, Closing price Fri, May 16 2025
+0.38 6.91%
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Key metrics

Market capitalization $3.71m
Enterprise Value $33.94m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 2.90
P/S ratio (TTM) P/S ratio 0.32
P/B ratio (TTM) P/B ratio 0.40
Revenue growth (TTM) Revenue growth 19.75%
Revenue (TTM) Revenue $11.69m
EBIT (operating result TTM) EBIT $-30.83m
Cash position $8.00m
EPS (TTM) EPS $-233.19
P/E forward negative
P/S forward 0.26
EV/Sales forward 2.42
Short interest 17.80%
Show more

Is Jaguar Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

Jaguar Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Jaguar Health, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Jaguar Health, Inc.:

Buy
100%

Financial data from Jaguar Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
12 12
20% 20%
100%
- Direct Costs 4.31 4.31
5% 5%
37%
7.38 7.38
31% 31%
63%
- Selling and Administrative Expenses 19 19
4% 4%
165%
- Research and Development Expense 17 17
11% 11%
141%
-28 -28
10% 10%
-244%
- Depreciation and Amortization 2.36 2.36
1% 1%
20%
EBIT (Operating Income) EBIT -31 -31
9% 9%
-264%
Net Profit -38 -38
7% 7%
-329%

In millions USD.

Don't miss a Thing! We will send you all news about Jaguar Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jaguar Health, Inc. Stock News

Neutral
Seeking Alpha
about 23 hours ago
Jaguar Health, Inc. (NASDAQ:JAGX ) Q1 2025 Earnings Conference Call May 15, 2025 4:15 PM ET Company Participants Lisa Conte – Founder, President, and Chief Executive Officer Carol Lizak – Chief Financial Officer Conference Call Participants Operator Greetings, and welcome to Jaguar Health's May 15, 2025 Investor Webcast. Before I turn the call over to management, I'd like to remind you that man...
Neutral
Accesswire
one day ago
The combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescription products, including license revenue, decreased approximately 6% versus net Q1 2024 revenue of $2.4 million and 37% versus net Q4 2024 revenue of $3.5 million  Mytesi prescription volume increased by approximately 1.8% in Q1 2025 over Q1 2024 and decreased by approximately 13.5% in Q1 2025 over Q...
Neutral
Accesswire
2 days ago
Click here to register Company plans to file its Earnings Report on May 15, 2025 on Form 10-Q for the quarter ended March 31, 2025 SAN FRANCISCO, CA / ACCESS Newswire / May 14, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast tomorrow, Thursday, May 15, 2025, at 4:15 p.m. Eastern to review first-quarter 2025 financials and provide corpor...
More Jaguar Health, Inc. News

Company Profile

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Head office United States
CEO Lisa Conte
Employees 49
Founded 2013
Website www.jaguar.health

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today